Ottawa, ON / ACCESSWIRE / January 29, 2015 / The Board of Directors of Mindesta, Inc. (OTCBB:MDST) is pleased to announce the appointment of Dr. Stephen Houldsworth to it's advisory board of CTT Pharmaceuticals effective immediately:
"I am pleased to be working with CTT in an advisory role as they work to create evidence based medicines within the Cannabis arena using their novel drug delivery systems. At a time when medical Marijuana is seeing greater acceptance into main stream medicine, the technology and foresight of the team has created an exciting opportunity to advance the science and develop pharmaceutical products, backed by clinical data, for the betterment of the patient." said Stephen Houldsworth
Dr. Houldsworth received a BSc (Hons) in Chemistry from St. Andrews University and a PhD in Organic Synthesis from the University of Nottingham. In 1998, he joined Dalton Pharma Services were he progressed through several leadership positions over 10 years, culminating in his appointment as Director of Operations and Sales. During his tenure at Dalton, he oversaw the R&D laboratories (both process and analytical), API and Sterile Manufacturing Operations, Validation Group as well as the Facility Operations. In these more senior roles he spearheaded efforts to expand the company's capabilities, including overseeing the design, construction and commission of a new sterile filling operation for both liquid and powder doses. He was involved in the creation of the GMP systems and SOPs necessary to successfully pass Dalton's first regulatory audit.
In 2008 Dr. Houldsworth took a leadership role in the R&D group at Apotex Pharmachem Inc., the active pharmaceutical ingredient manufacturing division of Apotex Inc., Canada's leading generic manufacturing company. Three years later, Stephen took on an expanded role at the helm of portfolio management for Apotex Pharmachem Inc., which encompassed their eight wholly-owned or joint venture manufacturing sites around the world. This role has since expanded into the realm of business development for the North American and Israeli markets as Apotex Pharmachem seeks to establish itself as a third-party supplier of Active Pharmaceutical Ingredients to the pharmaceutical industry worldwide.
"Dr. Houldsworth brings a wealth of knowledge within the contract manufacturing space. His experience encompasses the full lifecycle of a drug from the R&D stage through to manufacturing within a GMP facility. As an advisor, we look to leverage his expertise and experience sourcing suppliers of APIs and setting up FDA-approved contract manufacturing facilities and laboratories. He will provide us with guidance in the regulatory area as we move forward with our strategy to manufacture evidence-based medicine out of Cannabis and opioid-based drugs using our patented technology of thin strips (oral wafers), said Dean Hanisch-President- CTT Pharmaceuticals
Dr. Modi- CEO, CTT Pharmaceuticals stated, "Dr. Houldsworth's analytical background in research and development within a sterile manufacturing operation coupled with his education in organic chemistry will be of significance as we look to create improved drug delivery in this relatively new field,"
ABOUT CTT PHARMACEUTICALS:
CTT Pharma has invented and developed an ideal intra-oral, sublingual, fast-dissolving wafer drug delivery system that will be coupled with a mobile backend tracking software designed to increase patient compliance and prevent physical addiction.
CTT Pharma's principal asset is a patented, orally administered, fast dissolving wafer (the "Wafer")
The Wafer formulation is protected by Canadian Patent Number CA 2624110 C and US Patent Number 8,823,401 B2. The Canadian Patent, is a blanket patent covering most pharmaceutical agents (an open patent) and US Patent consist of approved opiates; such as Fentanyl, Morphine, Codeine etc.
CTT Pharma's primary mission is to lower addiction and improve overall compliance within the pain management market, specifically opiates, through the use of improved drug delivery and novel IT technology. This technology platform will be targeting both the human and pet (Veterinarian) markets.
CTT Pharma's Oral fast dissolving drug delivery systems will consist of films and wafers that dissolve without water, within a few seconds after placement in the mouth. The majority of drugs administered using our drug delivery system, mirror injections in that they have the ability to enter the bloodstream quickly, are convenient and discrete, and can be administered anywhere. A faster absorption rate is achieved because the mouth contains a very thin mucosa and is extremely vascular. There is no bitter taste, no smoke inhalation as is the case with cannabis, and less degradation of medication (by bypassing the stomach) and most importantly lower dosage units are required given the efficiency of absorption. Patient compliance is improved, especially with those who have a fear of choking and/or are pediatric, geriatric or incapacitated patients who have difficulty swallowing.
Most fast dissolving systems on the market today deliver anti-inflammatories, antihistamines and cough and breathing related medications. CTT believes that its technology will be the first to gain widespread use in major markets such as Pain Management (MedWafe), Veterinary Medicine(VetWafe) as well as Medicinal Marijuana(Cannawafe).
For additional information, please contact:
Dean Hanisch, President
CTT Pharmaceuticals:
Tel: 613 612-6060
Website: www.cttpharmaceuticals.com
SOURCE: Mindesta, Inc.